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Summary
The Oct-3/4 transcription factor sustains embryonic stem (ES) cell self-renewal and is a dose-dependent cell fate determi-
nant. In the adult male, its expression is restricted to type A spermatogonia. We show that Oct-3/4 is expressed in all
human testicular germ cell tumors (GCTs) tested, even in the early premalignant component. We demonstrate that Oct-
3/4 dictates ES cells’ oncogenic potential in a dose-dependent manner; high levels increase the malignant potential of ES
cell-derived tumors while Oct-3/4 inactivation induces regression of the malignant component. Oct-3/4 expression in a
heterologous cell system transforms nontumorigenic cells and endows tumorigenicity in nude mice. Our findings suggest
that Oct-3/4 is not only a distinctive immunohistochemical marker for GCTs, but also plays a critical role in the genesis
of these tumors.
Introduction changes in the chromatin structure in the immediate upstream
regulatory region (Ben-Shushan et al., 1993). In the embryo,
Oct-3/4 expression is downregulated in trophoectoderm cellsTesticular germ cell tumors (TGCTs) are the most common ma-
lignancy in young adult Caucasian males and are responsible and becomes restricted to cells of the inner cell mass of the
blastocyst (Palmieri et al., 1994). From 8.5 days postcoitumfor 1 in 7 deaths in this group (Hellerstedt and Pienta, 2002;
Oliver, 1999). It is generally accepted that most types of TGCTs (dpc), expression cannot be detected in any somatic tissue of
the mouse embryo (Palmieri et al., 1994; Yeom et al., 1996).originate from the premalignant lesion intratubular germ cell
neoplasia (ITGCN) (Ulbright, 1993). However, little is known We have previously shown that in embryonal cells as well, the
Oct-3/4 gene, which is unmethylated in the blastula stage, un-about the genetic and molecular events that contribute to the
initiation and progression of this neoplastic process (Looijenga dergoes de novo methylation at 6.5 dpc and remains modified
in all adult tissues (Gidekel and Bergman, 2002). The expressionand Oosterhuis, 1999). Understanding these mechanisms may
bring about substantial advancements in understanding the ge- pattern of Oct-3/4 in embryonic and postnatal life suggests that
it plays a role as a “stem cell survival” factor. This is supportednetic and environmental factors that predispose men to these
tumors, as well as enable the development of targeted treatment by recent findings showing that loss of Oct-3/4 expression re-
sults in complete loss of pluripotent stem cells in early embry-modalities aimed at curing or preventing this disease in predis-
posed individuals. onic life (Nichols et al., 1998). Moreover, variations in Oct-3/4
levels alone (regardless of other genes) account for the majorityThe Oct-3/4 transcription factor plays a pivotal role as a key
regulator of pluripotency in the earliest stages of mammalian of failures currently observed for somatic cell cloning (Boiani et
al., 2002; Donovan, 2001). In the adult male mouse, expressiondevelopment (Brehm et al., 1998). It has been shown that a
critical amount of Oct-3/4 is required to sustain embryonal stem of Oct-3/4 is restricted to type A spermatogonia—the earliest
stage in the spermatocytic ontogeny. It is believed that Oct-3/4(ES) cell self-renewal, and any up- or downregulation induces
divergent cell fates. Lack of expression drives the formation of maintains the pluripotency of spermatogonial stem cells and
keeps them in an undifferentiated, self-renewing state (Pescetrophoectoderm, and elevated levels result in differentiation into
extra embryonic endoderm and mesoderm (Niwa et al., 2000). et al., 1998).
It has long been argued that tumors are maintained by aOct-3/4 expression is downregulated in ES cells that are treated
with retinoic acid (RA) (Okamoto et al., 1990; Palmieri et al., population of tumor stem cells (Reya et al., 2001). Because the
ability of Oct-3/4 to maintain the stem cell state of germ cells1994; Rosner et al., 1990; Scholer et al., 1989, 1990), and this
reduction is associated with increased DNA methylation and may be advantageous to cancerous cells, we hypothesized that
S I G N I F I C A N C E
Germ cell tumors (GCTs) are the most common cause of cancer death in young adult Caucasian males. The molecular events
leading to the development of these tumors are largely unknown. Here we provide evidence to suggest that the transcription factor
Oct-3/4, a known gatekeeper of germ cell fate in normal spermatogenesis, also plays a key role in GCTs. Moreover, we demonstrate
that it confers oncogenicity in a heterologous cell system and that downregulation of Oct-3/4 in established tumors induces regression
of the malignant component. Identification of the molecular mechanisms that underlie the generation of GCTs may open new
avenues for better understanding of the pathogenesis of this disease and for developing targeted therapeutic modalities.
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aberrant Oct-3/4 expression may contribute to the neoplastic
process in germ cells. A possible role for Oct-3/4 in germ cell
tumor evolvement is supported by several additional lines of
evidence. Oct-3/4 was initially identified in embryonal carcinoma
(EC) cells and is expressed in all EC cell lines assayed thus far
(Rosner et al., 1990). Moreover, our search of the CGAP data-
base identified Oct-3/4 transcripts in several cDNA libraries
prepared from primary GCTs (http://cgap.nci.nih.gov), and a
recent study using RT-PCR has shown that Oct-3/4 transcripts
are present in human GCTs (Palumbo et al., 2002). Thus, we
studied the possibility that aberrant expression of Oct-3/4 may
contribute to the neoplastic process in germ cells.
Results
Overexpression of Oct-3/4 in human germ cell tumors
To study whether the Oct-3/4 protein is expressed in human
cancer, we raised antibodies specific for the Oct-3/4 protein.
These antibodies gave a specific nuclear staining pattern in type
A spermatogonia cells in human testis (Figure 1A, arrowheads)
and not in either more mature sperm ontogeny or the sur-
rounding normal tissues (Figure 1A). Control antibody labeling
with preimmune rabbit serum was negative (data not shown).
A variety of human normal tissues and tumor samples (archival
preserved primary patient material) were tested for the presence
of Oct-3/4 protein using immunohistochemical staining. Oct-
3/4 expression was seen in all 45 primary human GCTs tested
exhibiting a range of expression levels (Figure 1). The variability
observed in Oct-3/4 expression could be due to inherent differ-
ences in the tumors or to differences in the preservation of
excised material. The GCTs that express Oct-3/4 include em-
bryonal carcinomas (Figures 1B–1F), seminomas (Figures 1G Figure 1. Oct-3/4 is overexpressed in human germ cell tumors
and 1H), and mixed germ cell tumors (in the malignant compo-
Immunohistochemical staining of Oct-3/4 protein expression in paraffin-
nent, Figures 1I and 1J). Interestingly, the strongest Oct-3/4 embedded human germ cell tumors sections.
nuclear staining was observed in carcinoma in situ (CIS) cells A: Intratubular germ cell neoplasia. The left seminiferous tubule contains
normal germ cells while the right seminiferous tubule is colonized by in situof ITGCN, Figure 1A, arrows), which represent the premalignant
neoplastic cells. Note that in the lower left tubule, normal spermatogenesiscomponent. Expression of Oct-3/4 in these CIS cells is higher
is seen and only the basal most spermatogonia are stained. In contrast,than in the adjacent normal type A spermatogonia. Non-GCT
the upper right tubule only contains Sertoli cells and neoplastic CIS/ITGCN
testicular tumors, including lymphomas (Figure 1K) and Sertoli cells that are intensely stained with anti-Oct-3/4.
cell tumors, were negative (Figure 1L). These results suggest B–C: Embryonal carcinoma. D–F: Embryonal carcinoma (different patient).
G–H: Seminoma. I–J: Teratoma with focal malignant component.that aberrant overexpression of Oct-3/4 is an early and possibly
K: Testicular lymphoma. The tumor cells occupying most of the section’sa contributory event in germ cell neoplasia.
area are negative while residual germ cells in a nearby seminiferous tubuleIn contrast to abundant Oct-3/4 expression in GCTs, Oct-
(upper left) show positive staining.
3/4 protein was not detected in an analysis of 182 solid tumors L: Testicular Sertoli cell tumor. The bar equals 100 M. The boxed areas are
that were sampled in a tissue array. This array contained sam- enlarged in the photomicrograph to their right.
ples from 16 lung tumors, 19 colon tumors, 7 stomach tumors,
7 liver tumors (primary hepatocellular carcinoma and metasta-
ses to the liver), 15 breast tumors, 14 ovarian tumors, 8 endome-
These tumors are morphologically similar to human immaturetrial carcinomas, 16 prostate carcinomas, 7 bladder carcinomas,
teratomas, a subtype of GCTs, and are characterized by the7 kidney carcinomas, 7 pancreatic cancers, 11 thyroid tumors,
presence of a mixture of mature and immature embryonal tis-14 skin tumors, 14 lymphomas, and 20 brain tumors. The array
sues (Ulbright, 1993). Human immature teratomas are gradedslide contained normal testicular tissue as well, which showed
into a four tiered system according to the relative abundancepositive Oct-3/4 staining and served as a positive control for
of primitive neural tissue present. Grade 0 tumors harbor nothe experimental procedure (data not shown). Therefore, our
immature tissue whereas grade 3 denotes an immature teratomafindings clearly show that Oct-3/4 is specifically expressed in
with abundant primitive tissue (Norris et al., 1976). While grade 0GCTs.
teratomas are benign lesions with a 5 year survival rate of 100%,
grade 3 teratomas are highly malignant tumors with a 5 yearAberrant expression of Oct-3/4 influences
survival rate of 33% for tumors that were considered to bethe malignant potential of the tumors generated
localized on operation (Zalel et al., 1996). Thus, the prognosisfrom inoculation of ES cells
is directly related to the percentage of immature tissue presentIt was shown previously that mice injected with either human or
murine ES clones develop mixed teratomas (Damjanov, 1987). in these tumors. Interestingly, immunohistochemical staining of
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Figure 2. Alterations in Oct-3/4 expression
change the tissue composition and malignant
potential of ES cell xenografts in Ola129/Sv mice
A–G: Histology of subcutaneous tumors derived
from: wt CGR8 ES cells (A–C); ZHTc25 ES cells
(D and F), and ZHTc25 ES cells treated with doxy-
cycline (dox, E and G). Panels A, D, and E were
stained with hematoxylin and eosin (H&E). Panels
B, F, and G show immunohistochemical staining
with anti-Oct-3/4, and panel C is stained with
anti-Ki-67. Black asterisks represent mature brain
tissue and red asterisks represent primitive brain
tissue. The bar equals 200 M. The percentages
reflect Oct-3/4 levels in the relevant cell line in
vitro under the appropriate dox treatment.
H: Tissue composition of the different xenografts
was determined by a systematic sampling analy-
sis of H&E-stained sections from all tumors (de-
scribed in Results). The relative frequencies of
mature brain and primitive brain tissue are
shown. Bars indicate standard error of the mean.
y axis—percent tissue; x axis—cell line and dox
treatment.
immature teratomas formed from wild-type (wt) ES cells showed 3/4 transgene. We used two kinds of Ola129/Sv ES cell lines
engineered by Niwa and collaborators (Niwa et al., 2000). Boththat while most of the tissue was negative for Oct-3/4 expres-
sion, all malignant foci, and some of the areas composed of types of cell lines harbor a tetracycline-inducible Oct-3/4 trans-
gene in which expression is induced after withdrawal of doxycy-primitive brain tissue, were positive for Oct-3/4 expression (Fig-
ures 2A and 2B). Staining of serial sections with an antibody cline (dox). The ZHTc6 and ZHTc25 clones are heterozygous
for the endogenous Oct-3/4 gene (Oct-3/4/), whereas in thedirected against the proliferation marker Ki-67 showed that Oct-
3/4-expressing foci are highly proliferative (Figure 2C). ZHBTc4 clone, both Oct-3/4 alleles are disrupted (Oct-3/4/).
Upon induction of the inducible transgene in ZHTc6 and ZHTc25Oct-3/4 expression level was previously shown to be a key
factor in determining the cell fate in the early embryo (Niwa et cells, Oct-3/4 levels increase to 150% relative to wt ES cells.
ZHBTc4 cells, harboring no functional endogenous Oct-3/4al., 2000). To address the possibility that various levels of Oct-
3/4 expression may affect the tumorigenic capacity of ES cells, gene, express the inducible transgene at a level of 50% of wt
levels, whereas in the presence of dox, these cells do not ex-we inoculated mice with ES cells that harbor an inducible Oct-
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Table 1. Incidence of tumor formation with the different ES cell clones and relative abundance of primitive and mature tissue
Oct-3/4 expression Incidence of tumor Primitive neuronal/ Primitive neuronal/total
Clone dox levels (%) formation (%) total tissue (%) neuronal tissue (%)
wt CGR8 ES  100 83 (15/18) 15.1  4.3 (n  4) 28  4 (n  4)
ZHTc25  75 70a (7/10) 11.7  3.3 (n  5) 24  7 (n  5)
ZHTc25  150 64a (9/14) 35.1  4.3d (n  5) 64  5e (n  5)
ZHBTc4  0 4.3b (1/23) NA NA
ZHBTc4  50 40c (8/20) NA NA
Mice were inoculated with the various clones and followed for tumor development with or without dox, as indicated. The relative Oct-3/4 expression levels
are inferred from the in vitro findings (Niwa et al., 2000). NA encodes not applicable.
a The difference in the incidence of tumor formation is not statistically significant from the incidence observed with wt ES cells; b p  0.0001 compared with
wt ES cells; cp  0.01 compared with wt ES cells; d p  0.01 compared with wt ES cells and with ZHTc25 cells with dox; e p  0.01 compared with ZHTc25
cells with dox and p  0.02 compared with wt ES cells. a–c Fisher’s exact probability test; d,e Mann-Whitney test.
press the Oct-3/4 protein at all (Niwa et al., 2000). Thus, these ing the relative proportion of different components in a sampled
tissue (Hammel et al., 1989).cleverly engineered ES cells that express Oct-3/4 at 0%–150%
allowed us to study the effect of different levels of Oct-3/4 on To this end, we found that mice that were inoculated with
ZHTc25 cells and given plain drinking water developed tumorsthe malignant potential of ES cells.
Cells from wt ES, ZHTc6, ZHTc25, and ZHBTc4 clones were that contained a higher proportion of primitive neural tissue
compared with tumors from dox-provided mice or with tumorsinjected subcutaneously into syngeneic Ola129/SV mice. Mice
inoculated with the ZHTc25 or ZHTc6 cells were either treated or from mice injected with wt ES cells (35.1%  4.3%, n  5
versus 11.7%  3.3%, n  5 and 15.1%  4.3%, n  4,not with 0.2 mg/ml dox in their drinking water. Tumors became
apparent at the site of injection within 2 to 4 weeks in 83% of respectively, p  0.01, Figure 2H and Table 1). In addition, we
calculated the percentage of primitive neural cells with regardthe mice injected with wt ES. Mice injected with ZHTc25 and
treated or not with dox-containing water developed tumors in to the total amount of neural tissue present in the tumor mass.
Again, upregulation of Oct-3/4 (Figure 2, compare F and G)70% and 64% of the cases, respectively. In marked contrast,
only 40% (p  0.01 compared with wt ES) of mice inoculated resulted in a higher percentage of primitive neural tissue in
ZHTc25 tumors in the absence of dox (64%  5%) versus thewith ZHBTc4 and given plain drinking water developed tumors,
and this percentage dropped to 4.3% when dox was added to presence of dox (24%  7%, p  0.01, Figure 2, compare D
and E), or in wt ES tumors (28% 4%, p 0.02). Similar resultsthe water (p  0.0001 compared with wt ES, Table 1). This is
not a result of decreased proliferative potential since in vitro were obtained with an additional independent clone, ZHTc6
(Figure 2H), indicating that this phenotype is a direct result ofthe proliferation rate of the various clones was found to be
similar (data not shown). These results suggest that lower levels upregulation of Oct-3/4 expression. Taken together, we found
that upregulating Oct-3/4 levels resulted in a higher proportionof Oct-3/4 expression (below 75%) hinder tumor formation.
To determine the effect of Oct-3/4 overexpression, mice of tumors containing primitive neural and malignant-appearing
tissues, compared with tumors having developed either frominjected with ZHTc25 cells were divided into groups maintained
either on plain water or on water supplemented with dox. These wt ES or from engineered ES cells in which Oct-3/4 levels are
kept low (Figure 2H and Table 1). These data bear relevance toanimals were sacrificed when the tumors reached the size of
1 cm2 for histological examination. The tissues were examined the corresponding human tumors since, as noted above, a
higher proportion of immature tissue indicates a more malignantfor the presence of primitive, mature, and malignant cells. Malig-
nant phenotype is characterized by the appearance of pleomor- behavior in these human tumors.
Mice injected with ZHBTc4 cells, expressing Oct-3/4 fromphic and hyperchromatic nuclei and abundant mitoses as evi-
denced by high power view of the tumors. Primitive brain tissue the transgene only, developed tumors that were enriched for
trophoblastic tissue as compared with a very low level of thisis characterized by neuropil packed with small neuroblast-like
cells with dark nuclei and high mitotic activity, while mature tissue in tumors evolving from injection of ZHTc25 cells
(11.2%  8.9%, n  5 versus 0.02%  0.03%, n  5, p brain is characterized by less crowding and the appearance of
differentiated neurons. Quantitation of these histological analy- 0.005, Figures 3A–3C). It is generally accepted that the different
subtypes of GCTs correspond to different lineages or stages inses were obtained from a systematic sampling analysis of hema-
toxylin- and eosin-stained sections from all tumors (Hammel et the developing embryo. For instance, seminoma is regarded as
a recapitulation of spermatogonia; embryonal carcinoma corre-al., 1989). Briefly, we randomly sampled ten microscopic fields
(1.1 mm 1.4 mm each) from each tumor for analysis. A matrix sponds to inner cell mass cells and choriocarcinoma to tropho-
blastic tissues (Chaganti and Houldsworth, 2000). In accor-of 20  20 dots was applied to each field, and tissue type for
each dot was assigned and recorded. The reader was blinded dance, the malignant component in ZHBTc4-derived tumors,
expressing lower levels of Oct-3/4, was mainly composed ofto the ES cell clone as well as to the mouse treatment group.
Thus, approximately 4,000 different points were analyzed per choriocarcinoma rather than embryonal carcinoma, typically
found in tumors derived from ZHTc25 and ZHTc6 cells. Astumor sample. The relative frequency of each tissue type as-
signed to all dots corresponds to the proportional volume of previously noted, only 1 mouse out of 23 (Table 1) injected with
ZHBTc4 cells and fed with dox developed a tumor. This tumorthis tissue type in the entire tumor. This labor intensive analysis
has previously been shown to be the optimal method for evaluat- was extremely small and composed of mature trophoblast cells
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Figure 3. Oct-3/4 downregulation induces re-
gression of the malignant component
A–I: ZHBTc4 ES cells were injected subcutane-
ously into the left flank of Ola129/Sv mice. After
reaching a size of 1 cm2, ZHBTc4 tumors were
maintained in the absence (A–C, H, and I) or
presence (D–F and G) of dox for another 2 weeks.
Xenografts were subjected to histological analy-
sis and stained with H&E (A–F) or with anti-Oct-3/4
(G–I). Green asterisks represent choriocarci-
noma foci and yellow asterisks represent the ma-
ture trophoblastic component. The bar equals
100 M. The boxed areas are enlarged in the
photomicrograph to their right.
J: The proportion of immature and malignant tis-
sue was recorded for each tumor (as described
in the text) and the mean and standard devia-
tion were calculated for each group. y axis—
percent malignant tissue; x axis—dox treatment.
with no immature areas (data not shown). Interestingly, our in from the stably integrated dox-regulated transgene since both
endogenous Oct-3/4 alleles were disrupted. To address thisvivo results clearly corroborate previously published in vitro
experiments showing that downregulating Oct-3/4 expression in question, mice were injected with ZHBTc4 cells, kept in the
absence of dox and followed for tumor appearance. Once tu-ZHBTc4 cells results in differentiation toward the trophoblastic
lineage (Niwa et al., 2000). Thus, our data suggest that also in mors reached the size of 1 cm2, mice were assigned to either
one of two groups: one treated with dox (12 mice) and the otherZHBTc4 cells, upregulating Oct-3/4 expression results in more
aggressive tumors, as judged by the abundance of malignant without (11 mice). After three weeks, the tumors were subjected
to histological analysis. Several sections were examined fromtissue, whereas low levels of Oct-3/4 expression are associated
with mature/differentiated tissue. Moreover, these results also each tumor and representative images are shown in Figure 3.
emphasize that Oct-3/4 expression is cardinal for tumor for- In all mice, administration of dox (resulting in downregulation
mation since ES cells devoid of Oct-3/4 hardly generated any of Oct-3/4 expression, Figure 3, compare G to H) was associated
tumors. with tumor regression, as evidenced by histological analysis
revealing mature tissue (Figures 3D–3F), large areas of fibrosis,
granulation tissue, and signs of hemorrhage. Remarkably, in aExpression of Oct-3/4 is required for maintenance
of the malignant phenotype subset of these tumors (4/12), complete disappearance of the
malignant component was observed following dox addition.ZHBTc4 cells provided us with the opportunity to investigate
whether Oct-3/4 expression is required for maintenance of the These findings are in complete contrast with abundant malig-
nant tissue found in all (11/11) mice not treated with dox (Figuresimmature tumor phenotype. These cells express Oct-3/4 only
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3A–3C). Quantitative assessment of the abundance of malignant
tissue revealed a 10-fold reduction in the mean percentage of
malignant tissue in tumors that grew in the presence of dox
compared with the untreated group (1.7%  0.1% versus
19%  0.9%, respectively, p  0.02, Figure 3J). These results
indicate that Oct-3/4 expression is essential for maintenance
of these tumors and suggest that Oct-3/4 functions as an
oncogene.
Oct-3/4 is a candidate oncogene in Swiss 3T3 cells
Several homeobox-containing genes were previously shown to
transform nontumorigenic fibroblasts in vitro (Maulbecker and
Gruss, 1993; Qin et al., 1994; Stuart et al., 1995; Soubeyran et
al., 2001). We set out to directly test the oncogenic potential
of Oct-3/4 in this system as well. Nontumorigenic Swiss 3T3
fibroblast cells were transfected with the Oct-3/4 expression
vector (pBL-Oct-3/4-EGFP), the empty vector (pBL-EGFP), and
as a positive control the oncogenic ras expression vector
(H-rasV12, pBpRas kindly provided by W.C. Hahn). Western blot
analysis of nuclear extracts and immunofluoresence staining
revealed that all the independent cell lines transfected with pBL-
Oct-3/4-EGFP expressed the Oct-3/4 protein in the nucleus,
whereas control cell lines did not (Figure 4A, showing represen-
tative clones). Four independent subclones from each group
were assayed for their ability to grow in soft agar. This experi-
ment was performed because loss of anchorage dependence is
a hallmark of tumor cells, and the ability to promote anchorage-
independent growth is a common property of oncogenes. Swiss
3T3 wt cells, as well as those harboring the pBL-EGFP vector
only, did not form colonies whereas ras-expressing cells did.
Remarkably, expression of Oct-3/4 stimulates formation of ro-
bust colonies in soft agar, with a cloning efficiency similar to
oncogenic ras (Figures 4B–4D and Table 2). Moreover, either a
point mutation in the DNA binding domain (Vigano and Staudt,
1996) or a deletion in the C-terminal region that harbors the
specific transcriptional activation domain (Brehm et al., 1997)
completely abrogated the ability of Oct-3/4 to form colonies in
soft agar (Table 2). These results indicate that Oct-3/4 shares
the ability to promote anchorage-independent growth with on-
cogene products, and both the DNA and the C-terminal trans-
activation domains play a crucial role in this ability.
To find out whether Swiss 3T3 cells expressing Oct-3/4 are
tumorigenic in vivo, cells expressing Oct-3/4, vector only, or
Figure 4. Oct-3/4-expressing Swiss 3T3 cells form colonies in soft agar and ras were injected subcutaneously into CD1 nude mice. None of
tumors in nude mice
the mice injected with the vector-only cells developed tumors
A: Western blot analysis of nuclear extracts from all the stably transfected within an eight-week observation period. In contrast, cells ex-clones generated from Swiss 3T3 cells was performed using anti-mouse Oct-
pressing either ras or Oct-3/4 formed bulky tumors in 10–183/4 serum. Oct-3/4 protein was detected in the clones transfected with
pBL-Oct-3/4-EGFP (shown is clone #16), V→P Oct-3/4 (shown is clone #7), days. Histological analysis of the Oct-3/4-expressing tumors
and C Oct-3/4 (shown is clone #1), but was absent in Swiss 3T3 cells stably showed that they are high-grade fibrosarcomas (Figure 4E) that
transfected with the pBL-EGFP vector only (shown is clone #8). 	-actin was aggressively invade adjacent tissues such as liver (F), kidney
used as a loading control. Immunofluorescence staining with antiserum
(G), muscle (H), and spinal cord and bone (I). This invasiveagainst Oct-3/4 was used to further verify the nuclear localization of the
phenotype was much more marked in the Oct-3/4-expressingprotein generated form the transgene.
B–D: Colony formation in soft agar of Swiss 3T3 cells stably transfected with tumors as compared with ras-expressing tumors, which tended
pBL-EGFP vector (B, negative control, clone #8); Ras expression vector to be localized and separated from the surrounding tissues by
(C, positive control), and pBL-Oct-3/4 expression vector (D, clone #16). a thin pseudo-capsule (Figure 4J).Photomicrographs were taken with a phase contrast microscope.
E: Photomicrograph of a tumor derived from an Oct-3/4-expressing clone
showing tumor necrosis (arrowheads).
F–I: Representative photomicrographs of hematoxylin- and eosin-stained
tumors derived from an Oct-3/4-expressing clone showing invasion into liver
J: Photomicrograph of a tumor derived from a ras-expressing clone com-(F, asterisk denotes liver tissue), kidney (G, asterisk denotes kidney tissue),
muscle (H), and spinal cord and bone (I, arrowhead marks spinal cord and posed of a high grade fibrosarcoma, circumscribed by a thin pseudocap-
sule (left). The bar equals 100 M.asterisk designates bone).
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of these tumors, the malignant component completely disap-Table 2. Incidence of anchorage-independent colonies in wt
and transfected Swiss 3T3 cells peared, whereas in others, there was a dramatic reduction in this
component as compared to abundant malignant tissue found inColonies per dish Cloning
Clone (mean  SEM) efficiency (%) tumors expressing Oct-3/4 throughout their growth. Downregu-
lation was accompanied by infiltration of inflammatory cells,wt 0 0
granulation tissue formation, and hemorrhage, all signs of tumorpBL-EGFP (#2, 8, 11) 0 0
Oct-3/4-#2 122.7  0.8 24.5 regression.
Oct-3/4-#3 107.0  1.6 21.4 Recent studies with switchable oncogenes in mouse tumor
Oct-3/4-#9 135.0  2.9 27.0 models suggest that some tumors depend on a single oncogeneOct-3/4-#16 126.0  1.2 25.2
for survival. This was shown for H-ras-dependent melanomas,V→P Oct-3/4 (#1, 6, 7) 0 0
C Oct-3/4 (#1, 11, 19) 0 0 K-ras-induced adenocarcinomas of the lung, BCR-ABL-induced
ras 149.3  2.0 29.8 leukemias, and Myc-induced leukemias, lymphomas, and islet
cell tumors (Chin et al., 1999; Felsher and Bishop, 1999a; FisherA total of 500 cells of each clone were seeded into 0.33% agar as described
in Experimental Procedures. Four different Oct-3/4-expressing clones, desig- et al., 2001; Huettner et al., 2000; Karlsson et al., 2003; van de
nated Oct-3/4-#3, #16 (Figure 4A), #9, and #2 were used. As negative Wetering et al., 2002). These findings suggest that human tu-
controls, three clones harboring the empty vector (designated pBL-EGFP mors may be similarly reversible with targeted therapy aimed at#2, #8, and #11); three clones harboring an Oct-3/4 gene carrying a non-
a single particular oncogene. Indeed, anti-Her-2/neu antibodiesfunctional DNA binding domain (a Val235 to Pro mutation, designated V→P
Oct-3/4 #1, #6, and #7); or three clones harboring an Oct-3/4 gene lacking are part of the standard treatment regimen for metastatic Her-
the C-terminal region that encodes the specific transcriptional activation 2/neu-overexpressing breast cancer (Yarden, 2001).
domain (designated C Oct-3/4 #1, #11, and #19) were used. A clone However, there are data to show that in other cases, tumors
harboring oncogenic ras was used as a positive control. Colonies (with 
40
do not remain dependent on the initiator oncogene for mainte-cells) were counted after 14 days of growth. Values represent averages of
nance of the transformed state (D’Cruz et al., 2001; Ewald ettriplicate dishes with standard error of the mean (SEM). Cloning efficiency
was calculated as the average number of colonies/number of cells seeded. al., 1996; Felsher and Bishop, 1999b; Jain et al., 2002). Thus,
it seems likely that the response of tumors to remediation of a
single genetic lesion will vary with the nature of the initiating
oncogene and the cellular lineage of the tumors. Our findings
showing residual malignant component in the tumor mass in aDiscussion
subset of the tumors where Oct-3/4 expression was downregu-
lated could result from secondary genetic changes that areIn this study, we used ES cell lines with dox-dependent Oct-
responsible for the transformed phenotype. Alternatively, it is3/4 expression to investigate whether Oct-3/4 can influence the
possible that we did not wait long enough for the disappearancetumorigenic phenotype of ES cells in a dose-dependent manner.
of the entire malignant component.Mice injected with either ZHTc6 or ZHTc25 cells, overexpressing
Our results, along with a very recent extensive studyOct-3/4, developed tumors with a more primitive and malignant
(Looijenga et al., 2003), show that Oct-3/4 is overexpressed inphenotype as compared with tumors that arose from injection
human GCTs, as early as the carcinoma in situ stage all theof the same cells in which Oct-3/4 expression is downregulated.
way through metastatic lesions. Oct-3/4 is normally expressedOct-3/4 was previously shown to serve as a dose-dependent
in the earliest stages of spermatogenesis (Pesce et al., 1998).cell fate/differentiation determinant. The level of Oct-3/4 expres-
Thus, these results fit well with the growing body of evidencesion dictates the cellular phenotype, with low levels driving dif-
that links cancer with genes and pathways that are required forferentiation toward trophoectoderm and high levels resulting in
normal embryonic patterning. In many cases, cancer seems todifferentiation into mesoderm and primitive endoderm lineages
be caused by the deregulation of transcription factors that affect(Niwa et al., 2000). In this study, we show that in mouse xeno-
cell fate and proliferation. Two well-studied examples are (1)grafts in vivo, Oct-3/4 influences the oncogenic fate in a dose-
the wnt pathway, which in normal intestine regulates cell fatedependent manner. ES cells expressing low levels of Oct-3/4,
and is involved in colon cancer through aberrant regulationZHBTc4, gave rise to tumors that were enriched for trophoblast
of 	-catenin (van de Wetering et al., 2002) and (2) the Sonictissue, whereas mice injected with ES cells containing high
hedgehog-Gli signaling pathway, which normally regulates epi-levels of Oct-3/4, ZHTc6 and ZHTc25, developed embryonal
dermal differentiation and whose inappropriate activation oc-carcinomas/primitive neural tumors. Moreover, we provide data
curs in several types of tumors, including those of brain andto show that expression of Oct-3/4 in a heterologous cell system
skin (Dahmane et al., 2001; Grachtchouk et al., 2000; Nilssonconfers a malignant phenotype upon these cells, evidenced by
et al., 2000). Interestingly, both Oct-3/4 and Gli proteins seemcolony formation in soft agar, tumorigenicity in nude mice, and
to be involved in tumors that are derived from tissues in whichthe appearance of histological hallmarks of malignancy such as
these proteins are active. These findings support the view thatmarked pleomorphism, invasiveness, and necrosis. This activity
many molecular pathways that underlie carcinogenesis repre-requires both the C-terminal and the DNA binding domains.
sent aberrations of the normal processes that control em-Therefore, our findings that Oct-3/4 confers a malignant pheno-
bryogenesis.type upon Swiss 3T3 cells, increases the malignant potential of
An additional example of deregulation of transcription fac-ES cells, and is ubiquitously expressed in all human GCTs from
tors that affect cell fate and proliferation are the homeoboxthe earliest detectable stage highly suggest that aberrant Oct-
genes, which encode transcription regulatory proteins that are3/4 expression may play a cardinal role in genesis of GCTs.
widely used during development and are often aberrantly ex-We have found that the tumors obtained from injection of
pressed in cancer (Abate-Shen, 2002; Stuart et al., 1995). AES cells that express Oct-3/4 only from a dox-inducible Oct-
3/4 transgene, ZHBTc4, regress after dox addition. In a subset number of these genes were shown to induce transformation
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lected from the archives of the Pathology Department of the Hadassah-of cells in culture and to form tumors in vivo (Maulbecker and
Hebrew University Medical Center, Jerusalem. In addition, a tumor tissueGruss, 1993). Oct-3/4 belongs to the POU transcription factor
array containing more than 180 different tumors was analyzed (Clinomicsfamily, a subset of the homeobox superfamily (Ryan and Rosen-
Biosciences Inc., Pittsfield, Massachusetts).
feld, 1997; Verrijzer and Van der Vliet, 1993). Thus, our results
suggesting that Oct-3/4 plays an important role in malignant Antibodies
transformation, in addition to its recognized role in develop- Polyclonal rabbit anti-sera directed against the human and the mouse Oct-
mental decisions, are in agreement with previously reported 3/4 proteins were raised in rabbits following injection of the full-length recom-
binant proteins (Ben-Shushan et al., 1998). Both antibodies react specificallydata pertaining to the bona fide homeobox genes.
with the human Oct-3/4 protein as illustrated by the specific immunohisto-What is the molecular mechanism by which Oct-3/4 directs
chemical staining of Oct-3/4 in type A spermatogonia as well as by specifictumors to a more primitive and malignant phenotype and what
electrophoretic mobility shift assay experiments (data not shown). For mostcauses the deregulation of Oct-3/4 expression in cancer? Oct-
of the immunohistochemical experiments, the anti-mouse Oct-3/4 serum
3/4 encodes a transcription factor that acts as a gatekeeper in was used as it gave a better signal to noise ratio. An anti-mouse Ki-67
early mammalian development (Pesce and Scholer, 2001). It antibody (clone Tec-3, DakoCytomation, Denmark) was used for proliferation
has been implicated in a variety of cellular functions including assays and an anti-mouse 	-actin antibody (clone AC-15, Sigma, St. Louis,
Missouri) was used for loading control in Western blot analyses.maintaining the pluripotent phenotype of ES cells and directing
differentiation to particular cellular lineages (Niwa et al., 2000).
Cell cultureIt is clear that Oct-3/4 cumulative activities provide a balance
Wild-type CGR8 ES cells, ZHTc25, and ZHBTc4 ES cells were culturedbetween proliferation and differentiation. Thus, it is reasonable
without feeders in LIF-supplemented medium in the presence or absence
to suggest that deregulated Oct-3/4 expression distorts the of dox as described previously (Niwa et al., 2000). Swiss 3T3 cells (Clontech
balance toward a transformed phenotype. In this context, it is Laboratories, Palo Alto, California) were maintained in DMEM supplemented
interesting to note that expression of the stem cell-specific with 10% fetal calf serum in the presence of G418 (250 g per ml, Invitrogen
growth factor fgf-4 (Wilder et al., 1997), which is one of Oct- Life Technologies, Carlsbad, California).
3/4’s putative target genes, is associated with human testicular
Plasmidstumors (Strohmeyer et al., 1991; Suzuki et al., 2001; Yoshida
pBL-Oct-3/4-EGFP was constructed by cloning the full-length Oct-3/4 cDNAet al., 1988). Furthermore, in the mouse testis, fgf-4-specific gain
into the PvuII site of pBL-EGFP (Clontech Laboratories). pBL-Oct-3/4-C75-of function resulted in markedly enhanced spermatogenesis
EGFP was constructed by deleting 400 bp harboring 75 codons from the
(Yamamoto et al., 2002). Therefore, the aberrant expression of 3 end of the Oct-3/4 cDNA and subcloning the construct in frame into the
the Oct-3/4 gene in cancer cells may lead to inappropriate PvuII site of pBL-EGFP. pBp-Ras was received from William C. Hahn (Stan-
activation of growth factors, which, in turn, promote cell prolifer- ford University, California) and the V-P construct was received from Maria
ation. Alessandra Vigano (degli Studi di Pavia Universita, Italy).
The widespread occurrence of Oct-3/4 expression in GCTs
DNA transfectionscould be due to dysregulation of either upstream activators of
Transfection of Swiss 3T3 cells was carried out using FuGENE6 transfectionOct-3/4 or mutations and deletions in the proteins that nega-
reagent following the manufacturer’s protocol (Roche, Basel, Switzerland).tively regulate Oct-3/4. Such mutations were detected in the
Cells (5  105) were plated 24 hr before transfection and cotransfected
adenomatous polyposis coli (APC) gene and were found to with 10 g of either pBL-EGFP vector, pBL-Oct-3/4-EGFP, or pBp-Ras
lead to 	-catenin overactivity in human cancers (Polakis, 2000; expression vectors together with 1 g of a plasmid carrying the Hygromycin
Taipale and Beachy, 2001). It was recently shown that	-catenin, B selection gene. Stably transfected cells were selected by Hygromycin B
together with TCF-4, constitutes the master transcriptional reg- (125 g per ml, Roche) and clonally propagated. The Oct-3/4 deletion mu-
tants expression vectors (10 g) were cotransfected together with 1 g ofulator that controls proliferation versus differentiation in intesti-
a plasmid carrying the Puromycin selection gene. Stably transfected cellsnal stem cells (van de Wetering et al., 2002). These results
were selected by Puromycin (5 g per ml, Roche) and clonally propagated.bring the analogy between Oct-3/4 and 	-catenin even closer.
It seems that both genes are master regulators of differentiation,
Soft agar assaywhich when aberrantly overexpressed pave the way to the de-
The soft agar assay was carried out in 60 mm culture dishes. Each dish was
velopment of cancer. coated with 4 ml of medium containing 0.55% soft agar. Triplicates of 0.5 
The genetic mechanisms by which wt ES cells generate 103 cells were suspended in 3.6 ml of growth medium, mixed with 0.4 ml
tumors in vivo are poorly understood. It is possible that since of 3.3% soft agar, and added to the dishes. Cells were fed weekly with 0.5
ml of medium. After 14 days, colonies were counted.stem cells have the machinery for self-renewal already activated,
maintaining this activation may be a simpler task than turning
Protein analysisit on de novo. Our data clearly show that high levels of Oct-3/4
For Western immunoblot analysis, nuclear extracts (Ben-Shushan et al.,expression increase the malignant potential of ES cells and are
1993) from the various Swiss 3T3-transfected cells were loaded on 6% SDS-detected in GCTs. If Oct-3/4 is essential for tumor survival in
PAGE (7.5g total protein/lane) along with extract from P19 EC cells (positive
established human GCTs, then eliminating Oct-3/4 may be a control) and transferred to nitrocellulose membrane (Protran, Schleicher and
valid gene-directed therapy. Indeed, our oct-3/4 downregulation Schuell, Dassel, Germany). The blots were probed with antibodies against
studies support this notion. The fact that in the adult, Oct-3/4 Oct-3/4 or 	-actin, developed with HRP-conjugated secondary antibodies
is expressed in germ cells only and is probably not necessary (ImmunoPure, Pierce, Rockford, Illinois), detected by chemiluminescence
following the manufacturer’s protocol (ChemiLucent detection system,for any other tissue makes this approach even more appealing
Chemicon, Temecula, California), and visualized by exposure to X-ray film.as a possible safe target for gene-directed therapy.
Mouse xenograft assayExperimental procedures
Cells were trypsinized and resuspended in PBS. 6  106 viable wt Swiss
3T3 cells or transfected clones with either pBL-EGFP, pBL-Oct-3/4-EGFP,Clinical samples
or pBp-Ras were injected subcutaneously into the left flank of Cd1 nudeForty-five GCTs including embryonal carcinoma, seminoma, and mixed germ
cell tumor samples, in addition to 4 non-GCT testicular tumors, were col- mice. In the case of wt CGR8 ES cells, ZHTc6 and ZHTc25, 2  106 viable
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distribution and level in mouse clones: consequences for pluripotency.cells were injected subcutaneously into the left flank of Ola129/Sv mice. In
Genes Dev. 16, 1209–1219.the case of ZHBTc4 ES cells, 3  106 viable cells were resuspended in 0.2
ml PBS-Basement membrane matrix 1/1 (MatrigelTM, Biological Industries, Brehm, A., Ohbo, K., and Scholer, H. (1997). The carboxy-terminal transacti-
Kibbutz Beit Haemek, Israel) before subcutaneous injection into Ola129/Sv vation domain of Oct-4 acquires cell specificity through the POU domain.
mice. When appropriate, dox was delivered by the addition of 0.2 mg/ml Mol. Cell. Biol. 17, 154–162.
doxycycline (D-9891, Sigma-Aldrich Israel, Rehovot, Israel) to their drinking
Brehm, A., Ovitt, C.E., and Scholer, H.R. (1998). Oct-4: more than just awater. Bi-dimensional measurements of the tumors were obtained every 2
POUerful marker of the mammalian germline? Apmis 106, 114–124; discus-days with calipers, and animals were sacrificed either when the tumors
sion 124–116.reached the size of 1 cm2 or 12 weeks after injection. Tumors were weighed,
fixed in formalin, and embedded in paraffin for immunohistochemical analy- Chaganti, R.S., and Houldsworth, J. (2000). Genetics and biology of adult
sis. For tumor regression experiments, mice were inoculated with 3  106 human male germ cell tumors. Cancer Res. 60, 1475–1482.
ZHBTc4 ES cells, as above, and followed for tumor development. When
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen,tumors reached a size of 1 cm2, mice were randomly assigned to either one
Q., O’Hagan, R., Pantginis, J., Zhou, H., et al. (1999). Essential role forof two groups: one fed with plain water and the other with water supple-
oncogenic Ras in tumour maintenance. Nature 400, 468–472.mented with dox. Mice were kept for an additional 2 weeks.
Dahmane, N., Sanchez, P., Gitton, Y., Palma, V., Sun, T., Beyna, M., Weiner,
Histology, immunohistochemistry, and H., and Ruiz i Altaba, A. (2001). The Sonic Hedgehog-Gli pathway regulates
immunofluorescence staining dorsal brain growth and tumorigenesis. Development 128, 5201–5212.
Formalin-fixed, paraffin-embedded xenograft samples were cut into 5 m
Damjanov, I. (1987). Human yolk sac carcinoma antigens–a step beyondsections, deparaffinized in xylene, and rehydrated through a series of de-
alpha-fetoprotein. Lab. Invest. 57, 347–349.creasing concentrations of ethanol. Sections were stained with hematoxylin
and eosin or with the indicated antibodies. For immunofluorescence staining, D’Cruz, C.M., Gunther, E.J., Boxer, R.B., Hartman, J.L., Sintasath, L., Moody,
cells (5  105) were allowed to adhere to glass coverslips pretreated with S.E., Cox, J.D., Ha, S.I., Belka, G.K., Golant, A., et al. (2001). c-MYC induces
0.2% gelatine. Twenty-four hours later, cells were washed with 1 PBS and mammary tumorigenesis by means of a preferred pathway involving sponta-
fixed in 3.7% paraformaldehyde, permeabilized with 0.2% triton x-100, and neous Kras2 mutations. Nat. Med. 7, 235–239.
blocked with 1% BSA. The slides were incubated with antibody against the
Donovan, P.J. (2001). High Oct-ane fuel powers the stem cell. Nat. Genet.mouse Oct-3/4 protein for 40 min at 25c and than washed with PBS.
29, 246–247.Secondary antibody conjugated to FITC (Jackson Immunoresearch Labora-
tory Inc., West Grove, Pennsylvania) was then used to detect Oct-3/4 immu- Ewald, D., Li, M., Efrat, S., Auer, G., Wall, R.J., Furth, P.A., and Hennighausen,
noreactivity. The slides were examined and photographed. L. (1996). Time-sensitive reversal of hyperplasia in transgenic mice express-
ing SV40 T antigen. Science 273, 1384–1386.
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